Table 1.
Baseline characteristics of CAD patients with or without AVSc
| AVSc | Non‐AVSc | P value | |
|---|---|---|---|
| (n = 183) | (n = 164) | ||
| Age, years | 74.00 (66.00, 80.00) | 61.00 (56.00, 68.00) | <0.001 |
| Male, sex | 117 (63.93%) | 85 (51.83%) | 0.022 |
| Smoking | 57 (31.15%) | 41(25.00%) | 0.204 |
| Alcohol use | 21 (11.5%) | 17 (10.37%) | 0.741 |
| Hypertension | 144 (78.69%) | 109 (66.46%) | 0.011 |
| DM | 73 (39.89%) | 51 (31.10%) | 0.088 |
| Fasting blood‐glucose | 5.02 (4.56, 5.95) | 4.92 (4.50, 5.68) | 0.451 |
| Hb1Ac% | 6.00 (5.70, 6.80) | 5.90 (5.60, 6.40) | 0.029 |
| TG mmol/L | 1.30 (0.98, 2.01) | 1.47 (1.17, 2.07) | 0.034 |
| TC | 3.85 (3.13, 4.53) | 3.95 (3.36, 4.62) | 0.086 |
| HDL | 1.05 (0.91, 1.23) | 1.10 (0.96, 1.29) | 0.045 |
| LDL mmol/L | 2.25 (1.74, 2.99) | 2.32 (1.72, 2.89) | 0.956 |
| rGT mmol/L | 21.00 (15.00, 29.00) | 19.00 (12.25, 30.00) | 0.295 |
| eGFR mL/min/1.73 m2 | 72.51 ± 19.24 | 87.06 ± 17.46 | <0.001 |
| T‐PA pg/mL | 2131.22 (1415.44, 2690.03) | 1495.85 (1043.11, 2145.82) | <0.001 |
| Aspirin usage | 156 (85.25%) | 108 (65.85%) | <0.001 |
| ACEI/ARB | 121 (66.12%) | 106 (64.63%) | 0.771 |
| Beta‐blocker | 139 (75.96%) | 104 (63.41%) | 0.011 |
| Statin | 156 (85.25%) | 121 (73.78%) | 0.008 |
ACEI, angiotensin‐converting enzyme inhibitors; ARB, angiotensin receptor blockers; BMI, body mass index; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; rGT, γ‐glutamyl transferase; HDL, high density lipoprotein; LDL, low density lipoprotein; TG, triglyceride; TC, total cholesterol; T‐PA, tissue plasminogen activator.